Answers are grounded in this paper and cite their sources.
Phase 1 trial investigates safety and effects of MM-302 on advanced HER2-positive breast cancer, indicating potential treatment advancements.
BACKGROUND: This phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody-liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer. METHODS: ) q3w. RESULTS: Cu-labeled MM-302 visualized tumor-drug penetrance in tumors throughout the body, including the brain. CONCLUSION: plus 6 mg/kg trastuzumab q3w.
No takes yet. Share an insight, caveat, or question.
Münster et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: